The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales: Beinfeld, Molly, Atlas, Steven J, Touchette, Daniel, McKenna, Avery, Rind, David, Pearson, Steven D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Perspectives on Value
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391138/
https://www.ncbi.nlm.nih.gov/pubmed/34057394
http://dx.doi.org/10.18553/jmcp.2021.27.6.797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391138/
https://www.ncbi.nlm.nih.gov/pubmed/34057394
http://dx.doi.org/10.18553/jmcp.2021.27.6.797

Ejemplares similares